ATE542535T1 - Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten - Google Patents
Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheitenInfo
- Publication number
- ATE542535T1 ATE542535T1 AT06724715T AT06724715T ATE542535T1 AT E542535 T1 ATE542535 T1 AT E542535T1 AT 06724715 T AT06724715 T AT 06724715T AT 06724715 T AT06724715 T AT 06724715T AT E542535 T1 ATE542535 T1 AT E542535T1
- Authority
- AT
- Austria
- Prior art keywords
- prevention
- treatment
- azapaullone
- autoimmune diseases
- pancreatic autoimmune
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05009846 | 2005-05-04 | ||
EP05015986 | 2005-07-22 | ||
EP05023168 | 2005-10-24 | ||
EP06001327 | 2006-01-23 | ||
PCT/EP2006/004186 WO2006117221A1 (en) | 2005-05-04 | 2006-05-04 | Use of azapaullones for preventing and treating pancreatic autoimmune disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE542535T1 true ATE542535T1 (de) | 2012-02-15 |
Family
ID=36625260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06724715T ATE542535T1 (de) | 2005-05-04 | 2006-05-04 | Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten |
Country Status (4)
Country | Link |
---|---|
US (1) | US7968535B2 (de) |
EP (1) | EP1879591B8 (de) |
AT (1) | ATE542535T1 (de) |
WO (1) | WO2006117221A1 (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2240481A1 (de) | 2008-01-11 | 2010-10-20 | Albany Molecular Research, Inc. | (1-azinon)-substituierte pyridoindole als mch-antagonisten |
WO2010123919A2 (en) | 2009-04-20 | 2010-10-28 | Auspex Pharmaceuticals, Llc | Piperidine inhibitors of janus kinase 3 |
US9073925B2 (en) | 2009-07-01 | 2015-07-07 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
US8618299B2 (en) | 2009-07-01 | 2013-12-31 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof |
US8629158B2 (en) | 2009-07-01 | 2014-01-14 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
EP2448585B1 (de) | 2009-07-01 | 2014-01-01 | Albany Molecular Research, Inc. | Azinon-substituiertes azepin[b]indol und pyrido-pyrrolo-azepin mch-1 antagonisten, verfahren zur herstellung und verwendung davon |
US8993765B2 (en) | 2010-12-21 | 2015-03-31 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof |
WO2012088038A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof |
WO2012088157A2 (en) * | 2010-12-22 | 2012-06-28 | Amylin Pharmaceuticals, Inc. | Glp-1 receptor agonists for islet cell transplantation |
EP3920885A1 (de) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproinsäureverbindungen und wnt-agonisten zur behandlung von ohrerkrankungen |
JOP20210298A1 (ar) | 2019-05-14 | 2023-01-30 | Provention Bio Inc | طرق وتركيبات للوقاية من مرض السكري من النوع الأول |
IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2804959B1 (fr) * | 2000-02-15 | 2006-04-28 | Centre Nat Rech Scient | Utilisation de derives de paullones pour la fabrication de medicaments |
DE10290025T1 (de) * | 2001-04-19 | 2003-10-09 | Develogen Ag | Verfahren zur Differenzierung von Stammzellen in Insulin-produzierende Zellen |
CA2455753A1 (en) | 2001-08-03 | 2003-02-13 | Novo Nordisk A/S | Novel 2,4-diaminothiazole derivatives |
CN1646535A (zh) * | 2002-02-22 | 2005-07-27 | 帝人株式会社 | 吡咯并嘧啶衍生物 |
JP4414232B2 (ja) * | 2002-03-05 | 2010-02-10 | イーライ リリー アンド カンパニー | キナーゼ阻害物質 |
US8048454B2 (en) * | 2004-03-09 | 2011-11-01 | Michael Martin | Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (GSK-3) |
WO2005104836A2 (en) * | 2004-04-16 | 2005-11-10 | Albert Einstein College Of Medicine Of Yeshiva University | Drosophila models for diseases affecting learning and memory |
-
2006
- 2006-05-04 US US11/913,486 patent/US7968535B2/en not_active Expired - Fee Related
- 2006-05-04 AT AT06724715T patent/ATE542535T1/de active
- 2006-05-04 EP EP06724715A patent/EP1879591B8/de not_active Not-in-force
- 2006-05-04 WO PCT/EP2006/004186 patent/WO2006117221A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP1879591A1 (de) | 2008-01-23 |
US7968535B2 (en) | 2011-06-28 |
US20080287423A1 (en) | 2008-11-20 |
EP1879591B8 (de) | 2012-04-04 |
EP1879591B1 (de) | 2012-01-25 |
WO2006117221A1 (en) | 2006-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE542535T1 (de) | Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten | |
NL301145I2 (nl) | Tirbanibulin | |
BRPI0808775A2 (pt) | compostos e composições como moduladores de atividade de gpr119 | |
TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
MX2007010560A (es) | Roflumilast para el tratamiento de diabetes mellitus. | |
ATE526991T1 (de) | Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen | |
MX2007009807A (es) | Agentes terapeuticos de aptameros utiles en el tratamiento de trastornos relacionados con el complemento. | |
PL1910338T3 (pl) | Związki heterotetracykliczne jako mimetyki TPO | |
EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
ATE521608T1 (de) | Glucokinaseaktivatoren | |
WO2006091459A3 (en) | Compositions and methods for treating vascular permeability | |
MX2008006076A (es) | Metodos, composiciones y kits para el tratamiento de condiciones medicas. | |
DE602005009748D1 (de) | 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors | |
MX2008002166A (es) | Compuestos y composiciones como mimeticos de trombopoietina (tpo). | |
EA200702358A1 (ru) | Комбинация ингибитора pde4 и производного тетрагидробиоптерина | |
TW200716140A (en) | Treatment of inflammatory conditions | |
WO2006119329A3 (en) | Compositions and methods for the treatment of neurodegenerative diseases | |
TWI319708B (en) | Methods and compositions for altering cell fuction | |
DE602006008643D1 (de) | Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie | |
ATE429645T1 (de) | Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten | |
WO2008115469A3 (en) | Role of hedgehog signaling in atherosclerosis and cardiovascular disease | |
WO2009009417A3 (en) | Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion | |
TW200716132A (en) | Novel chemical compounds | |
MX2007005526A (es) | Tratamiento de mastitis con enrofloxacino. | |
DE602006018725D1 (de) | Amidin-derivate zur verwendung in der vorbeugung oder behandlung von glaukom |